Significant endocrine therapy-resistant tumor proliferation is present in ≥20% of estrogen receptor positive (ER + ) primary breast cancers and is associated with disease recurrence and death.
Introduction:
Resistance to endocrine therapy remains a significant cause of death for the ~175,000 women diagnosed each year with Estrogen Receptor positive (ER + ) breast cancer (1) . While some headway has been made in understanding underlying mechanisms, the majority of cases remain unexplained (1) . Traditionally, growth factor receptor pathway activation has been implicated as one underlying mechanism of acquired resistance to endocrine therapy. Recently, studies of endocrine therapy resistance in metastatic breast cancer, where patients have been exposed to long periods of treatment, have identified the acquisition of mutations in the estrogen receptor gene (ESR1) causing ligand-independent activation and aromatase inhibitor (AI) resistance to constitute an alternative underlying mechanism for endocrine resistance in the advanced disease setting (2) (3) (4) . However, ER+ primary breast cancer can also be endocrine therapy resistant at diagnosis (intrinsic resistance) where ESR1 mutations cannot be the sole explanation, as they are too rare. Intrinsic endocrine resistance is easily diagnosed, based on failure to fully suppress Ki67 (proliferation marker) in tumor biopsies after 2-4 weeks of neoadjuvant endocrine treatment(5) but is relatively understudied. Intrinsic resistance, as assayed by Ki67, occurs in at least 20% of ER + HER2 -tumors and is an established poor prognosis marker. Unfortunately these tumors also often also fail to respond well when switched to neoadjuvant chemotherapy (6, 7) . Consequently, patients diagnosed with intrinsically endocrine resistant ER + HER2 -primary breast cancer suffer high rates of relapse and death.
The recently noted correlation between high mutation load and poor prognosis in ER + breast cancer suggests that defects in DNA damage repair (DDR) genes may constitute an under-explored driver of endocrine therapy resistance (8) . While the best-understood DDR defect in breast cancer concerns homologous recombination (HR) deficiency, due to BRCA1/2 loss(9), this mechanism is less pertinent to ER + disease, which is largely HR-competent. A few preliminary epidemiological studies have noted possible roles for Base Excision Repair (BER)
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Author Manuscript Published OnlineFirst on August 11, 2017 ; DOI: 10.1158/2159-8290.CD- and Nucleotide Excision Repair (NER) in ER + disease pathogenesis (10, 11) . However, our investigations, reported here, establish a new role for a subset of mismatch repair (MMR) pathway components in regulating intrinsic endocrine therapy resistance in ER + disease. Using in vitro and in vivo models, we demonstrate that defects in MutL complex genes (MLH1, PMS1, PMS2) directly induce endocrine therapy resistance because an intact MutL complex enables an endocrine therapy activated ATM/CHEK2-dependent cell cycle checkpoint control to suppress CDK4 activity. We also use preclinical and neoadjuvant clinical trial data to demonstrate that deregulated CDK4 in MutL-deficient tumors remains targetable by CDK4/6 inhibition (CDK4/6i), explaining the activity of these agents in a subset of endocrine therapy resistant disease and thereby suggesting a new class of predictive markers for CDK4/6 targeted drugs.
Results

Role of DNA damage repair dysregulation in ER + breast cancer.
Since high mutation load is a marker of poor prognosis in ER + breast cancer(8), we first assessed correlations between mutation load and incidence of non-silent mutations in pathway-unique genes of the five major DDR pathways: MMR, BER, NER, non-homologous end joining (NHEJ) and HR in ER + human breast tumors. We chose two clinical datasets with whole exome sequencing data for this analysis: (i) several neoadjuvant aromatase inhibitor (AI) trials, collectively termed NeoAI, (Z1031, a study from the American College of Surgeons Oncology Group, which is now part of the Alliance for Clinical Trials in Oncology (6) , and the multi-institutional Preoperative Letrozole Phase 2 study (POL) (12) ) and (ii) the TCGA dataset (13) . Only mutations in MMR genes were significantly associated with increased tumor mutation load in both clinical datasets (Fig 1a-b) .
Since MMR genes are known to be dysregulated at the gene expression level, the impact of low MMR gene expression (using TCGA definitions of mean-1.5x standard deviation to avoid threshold training) on mutation load was also assessed in both datasets and a correlation
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Mismatch repair dysregulation and endocrine therapy resistance in ER
+ breast cancer patients.
Next, the effect of low RNA levels of each unique MMR gene on ER + breast cancer outcome of patients treated with hormone therapy (tamoxifen or AI) was assessed in the METABRIC dataset, chosen for its large sample size and long-term clinical follow-up (14) . Analysis in this dataset using the same cut-point for low expression drawn from the TCGA analysis (Fig S1a-b) revealed significant association between low RNA and poor overall (Fig 1c) and disease-free survival (Fig S1c-d ) in 3/8 canonical MMR genes: MLH1, PMS1 and PMS2. The poor prognostic effects were independent for each gene and were significant after correction for multiple testing (Table 1) .
MLH1, PMS1
and PMS2, along with MLH3, constitute the MutL complex of the MMR pathway. Therefore, the finding that only these three genes negatively affect overall and disease-free survival suggested a specific role for the MutL complex in poor outcome ER + disease. The MutL complex is recruited to DNA mismatches by the MutS complex (MSH genes), whereupon it performs two functions: first, to recruit repair proteins to the mismatched nucleotide and second, to activate ATM/Chk2 signaling in the event of unsuccessful repair (15) .
The coordinating protein in the MutL complex is MLH1 which, when heterodimerized with PMS1/2, forms a stable complex that is translocated to the nucleus (12) . In contrast, MLH3 is largely involved in post-meiotic recombination although it can play a compensatory role in MMR in the absence of MLH1 (16) (Fig 1d) .
Interestingly the hazard ratio for MutL
-was comparable to the adverse effects of HER2 amplification (Fig 1d+S1e) . Fig 1e) .
Interestingly, 11 tumors assigned as MutS-by mutation or under-expression of MutS were largely endocrine therapy sensitive with a significant fall in Ki67 (p=0.02) and no difference in Ki67 change compared to the MutS+ group (Fig 1e) .
To estimate the relative frequency of MutL -in endocrine therapy resistant ER + breast cancers, we examined the incidence of either non-synonymous mutations or low mRNA levels in the subset of AI resistant tumors from NeoAI (Ki67>10% on AI treatment). In this setting of poor responders), was enriched in endocrine therapy resistant tumors (Fig 1f) Fig S2a-b) . As previously published (16, 18, 19) , PMS1 silencing also induced loss of stability of MLH1 protein (Fig S2b) . Suppression of any one of the three MutL genes in either MCF7 or T47D cells induced resistance to all classes of endocrine interventions:
i.e. estrogen deprivation, a surrogate for AI exposure (Fig 2a+S2c) , fulvestrant and tamoxifen (Fig 2b+S2d) within a week of administration. In contrast, suppression of MSH2 did not affect response to estrogen stimulation (Fig 2a) or to fulvestrant-mediated ER degradation (Fig S2e) .
All further experiments were conducted using pharmacologically relevant 100nM doses of fulvestrant and tamoxifen, and largely in shMLH1 (MLH1 -) cells because of the central importance of MLH1 to MutL complex formation.
Pooled CRISPR-mediated disruption of each of MLH1, PMS1 and PMS2 genes in both MCF7 and T47D cell lines orthogonally supported a causal association between MutL -and response to fulvestrant (Fig S2f-g ) and to estrogen stimulation (Fig S2h) . Of note, CRISPRmediated knockdown of MutL genes was less well tolerated in T47D than in MCF7 cells (Fig   S2i) , and PMS2 knockdown by shRNA or CRISPR was not well tolerated in either cell line ( Fig   S2b+i) . These data might explain why PMS2 somatic mutations in human breast tumors are characteristically missense as complete loss of function may reduce cell viability, but may also be a reflection of the low baseline levels of PMS2 in MCF7 and T47D cells (approximately 30- (Fig 2c) , and unimpeded xenograft tumor growth after estrogen deprivation, as well as fulvestrant resistance (Fig 2d) . Critically, introduction of shRNA-resistant MLH1 cDNA into
MLH1
-cells (validated in Fig S3a) restored sensitivity to fulvestrant under both 2D (Fig S3a) and 3D growth conditions (Fig 2c) .
MutL dysregulation in patient-derived xenograft models. To confirm in vitro findings in a humanin-mouse breast cancer model, the occurrence of MutL gene mutation in patient-derived xenograft (PDX) tumors was examined. A missense mutation (E5K) in the MutL gene, PMS2, previously described in a hypermutator, MMR-deficient colorectal cancer cell line (HT-115) (CoSMiC), was identified in WHIM20, an ER + PDX(4) with high mutation load (Fig S3d) .
Notably, WHIM20 exhibits resistance to both fulvestrant treatment (Fig S3b) To understand the mechanism whereby MutL gene loss causes intrinsic endocrine therapy resistance, cell cycle activity after fulvestrant treatment was determined by immunofluorescence for pHistoneH3 (mitotic marker) staining in vitro (Fig 2e) and immunohistochemistry for Ki67 (proliferative marker) in xenograft tumors (Fig 2f) . Although basal cell cycle profiles were comparable between shLuc and shMLH1 cells (Fig S3g) , fulvestrant significantly inhibited proliferation of shLuc but not of shMLH1, shPMS1 or shPMS2 MCF7 and T47D cells (Fig 2e+S3h) . Similarly, MCF7 shMLH1 xenograft tumors demonstrated no measurable inhibition of proliferation after fulvestrant treatment, unlike their shLuc counterparts (Fig 2f) . These data suggest that loss of any member of the MutL complex prevents the anti-proliferative effects of ER blockade in ER + breast cancer cells.
Two screens were performed to explore underlying mechanisms. Fig S4a) , and of the 96 gene RNA levels assayed by qRT-PCR, 15 were significantly differentially regulated (shown in Fig S4b) by fulvestrant treatment in MutL -relative
Research. (Fig 3a) .
MutL complex genes are known to activate Chk2 during mismatch repair(21). We therefore proceeded to evaluate the role of Chk2 in mediating intrinsic endocrine therapy resistance. Down-regulation of Chk2 in MutL -relative to MutL + cells after fulvestrant treatment was observed in vitro by assessing levels of pChk2 and its downstream effectors, p21 and p27, in MCF7/shLuc relative to either shMLH1 (Fig 3b) or shPMS2 cells (Fig S4c) . In addition to down-regulation of pChk2 and more modestly, of p27/p21, up-regulation of p-Rb were observed in MLH1 -versus MLH1 + MCF7 xenograft tumors grown in the absence of estrogen (Fig 3c) . In spite of the heterogeneity of PDX tumors(22), WHIM20 tumors (#20, PMS2 E5K) also exhibited an almost complete inhibition of both total and p-Chk2 protein levels after estrogen deprivation, and fulvestrant treatment, in contrast to a MutL + , ER + PDX tumor, WHIM 16 (Fig 3d) . Both RPPA (Fig S4d) and mass spectrometry-based phosphoproteomics(22) (Fig S4e) (Fig 4a+S5c) . Unsurprisingly, shMLH1 cells did not upregulate MLH1 nuclear translocation (Fig S5c) , but neither did shPMS2 cells (Fig 4a+S5c) , supporting previously published evidence that the MutL complex requires heterodimerization to facilitate nuclear translocation(18). In corroboration, WHIM20 (PMS2 mutant) tumors had cytoplasmic but no detectable nuclear MLH1 on fulvestrant treatment, in contrast to MCF7 MutL + xenograft tumors (Fig 4a) . Consistent with these data, nuclear colocalization of p-ATM and p-Chk2 increased >4-fold (p<0.001) in MutL + cells after fulvestrant treatment but demonstrated no perceivable increase in MutL -(0.6-fold) MCF7 cells (Fig 4b) .
The lack of p-ATM/p-Chk2 foci in response to fulvestrant was also observed in MutL -WHIM20
tumors where pATM was virtually undetectable, although attenuated pChk2 nuclear foci were detected (Fig 4b) .
In support of these functional relationships, pooled siRNA used to transiently down-regulate either ATM or Chk2 in MCF7 parental cells induced resistance to both fulvestrant and tamoxifen within 48 hours (Fig 4c+d) , although transient downregulation of ATM, but not Chk2, also inhibited baseline growth of MCF7 cells (Fig S5d) . These results were confirmed in T47D cells (Fig S5e) , where transient downregulation of neither ATM nor Chk2 significantly affected baseline growth (Fig S5g) . Orthogonally, when ATM and Chk2 activation was inhibited pharmacologically(26) (validated in Fig S5f) , both MCF7 (Fig 4e+f) and T47D (Fig S6a+b) cells lost the ability to respond with growth inhibition to fulvestrant treatment. This phenotype appeared specific to Chk2, as neither an ATR inhibitor(27) nor a Chk1 inhibitor(28) could induce endocrine treatment resistance (Fig 4e+f, Fig S6a+b) . Moreover, ATM/Chk2 activation using the small molecule activator, 3,3'-diindolyl methane (DIM)(29) , (30) (validated in Fig S5e) , (Fig S7c) , suppression of either gene singly resulted in partial rescue of endocrine response in the MutL -cells (data not shown) but the combinatorial inhibition of both genes resulted in complete rescue of fulvestrant sensitivity in MCF7/MLH1 -cells (Fig 5b) . The next step in the proposed genetic pathway, loss of Chk2, was also tested for its role in CDK4/6 regulation in ER + breast cancer cells. Transient siRNA-induced suppression of Chk2 in MCF7
parental cells resulted in an immediate and significant increase in sensitivity to pharmacological CDK4/6 inhibition (CDK4/6i) (Fig 5c) , a result confirmed in T47D/MutL + cells (Fig S7e) . These
Research. growth inhibition over fulvestrant alone (Fig 5d, p=0.02 ). This difference was even more noticeable in T47D cells, where the combinatorial growth inhibition relative to fulvestrant alone went from ~25% in MutL + to >50% in MutL -cells (Fig S7i, p=0.005 ). Abemaciclib, in combination with fulvestrant, also inhibited 3D growth of MutL -cells (Fig 5e) . Of note, because CDK2, another G1/S cyclin-dependent kinase, was also upregulated at RNA levels in the cell cycle screen (Fig S7a) Three xenograft models were utilized for in vivo validation of response to CDK4/6
inhibition. MCF7 MutL -xenograft tumors regressed when treated with a combination of estrogen deprivation and palbociclib but not when treated with estrogen deprivation alone or with fulvestrant (Fig 5f+g) . Response of MutL-xenograft tumors to palbociclib was significantly higher than MutL+ MCF7 xenograft tumors (Fig 5f) , although the effect size was moderate.
CDK4/6i response was also validated in WHIM20 tumors, which demonstrated down-regulation of pRb in response to a combination of fulvestrant and palbociclib treatment but not in response to fulvestrant alone (Fig 5h) . WHIM20 tumors also demonstrated significant inhibition of tumor growth in response to either palbociclib alone or to the combination of palbociclib and fulvestrant (Fig 5i) . Finally, a second PDX model, HCI-005 with a frameshift mutation in PMS1, also demonstrated endocrine therapy resistance and significant palbociclib sensitivity (Fig 5j) .
These data together suggested that patients with MutL -ER + tumors can benefit from CDK4/6i despite intrinsic endocrine therapy resistance.
To obtain clinical data to support the postulate that MutL -tumors are sensitive to CDK4/6i, data from the NeoPalAna trial were examined(17). In this study (Fig 6a) , 50 patients presenting with clinical stage 2/3 ER + HER2 -breast cancer were treated with an AI, anastrozole, and biopsied after one month (C1D1). Palbociclib was then added to the treatment regimen with a further biopsy after ~2 weeks of combined treatment (C1D15). Patients then completed neoadjuvant treatment with the AI+CDK4/6i combination for approximately 16 weeks before surgery. Whole exome sequencing and RNA expression analysis were conducted on tumors with sufficient material (Fig 6b) . of AI and CDK4/6i than after AI alone confirming the activity of palbociclib in primary ER + breast cancer.
First, the Ki67 response of tumors based on mutations in MutL and MutS genes alone was analyzed (Fig 6c-e) . To serve as reference points in the analysis, the MutL + cases are divided into AI sensitive and resistant (AI sensitive=Ki67<10% after 4 weeks of AI). When considering mutations alone, six MutS mutant tumors were identified, five of which were AI sensitive, including a tumor with a truncating mutation in MSH5. The majority of the MutS mutant tumors also demonstrated CCCA with AI alone, although the addition of CDK4/6i incrementally increased treatment efficacy (Fig 6c+f) . Four MutL mutant tumors were identified (Fig 1e) . Consistent with our hypothesis, these tumors exhibited AI resistant proliferation and none demonstrated CCCA with AI alone. However, in keeping with the experimental data presented above, all four MutL-mutant tumors demonstrated significant Ki67 inhibition when palbociclib was added, with all of them achieving CCCA (Fig 6d) . Importantly, tumors with inactivating (nonsense or frame shift) mutations in MutL genes demonstrated the strongest endocrine therapy resistance phenotype and appeared most sensitive to CDK4/6i (Fig 6d) .
Next, dysregulation of MutL and MutS genes at both DNA and gene expression level (MutL -and MutS -groups) were determined as in previous analyses presented in Fig 1   (described in Fig 6f) . Using the combined definition, six MutL -and six MutS -tumors were identified from 37 tumors examined (two combined MutL and MutS deficient were excluded as not fitting a binary definition of deficiency). Again, four of the six MutS -tumors were AI sensitive, even exhibiting CCCA with AI alone (Fig 6f) , and only one of the tumors remained AI resistant (Fig 6e+f) . In contrast, 3/6 MutL -tumors were AI resistant (Ki67>10%) and 0/6 MutL -tumors demonstrated CCCA on AI alone (Fig 6f) . 
addition of palbociclib all six MutL -tumors achieved CCCA, with mean Ki67 levels falling from 13% on AI treatment to 1.3% on the combination.
Discussion
In this investigation we delineate a pathway involving the MutL complex, along with ATM, Chk2 and CDK4/6 that is required for ER + HER2 -tumors to respond to endocrine therapy (Fig 6g) . When components of this pathway are poorly expressed or lost through mutation, feedback control on CDK4/6 is defective. This allows the cell cycle to proceed despite DNA mismatches thereby promoting the growth of high mutation load ER + breast cancers that are intrinsically resistant to endocrine treatment, but still sensitive to CDK4/6i. Both CHEK2 and ATM are well-established breast cancer susceptibility genes with low to medium penetrance (42) . Interestingly, CHEK2 germline variants specifically associate with increased incidence of ER + tumors (43) , suggesting that the role of Chk2 in connecting ER to the cell cycle highlighted in our investigation is a fundamental pathway that contributes to development of luminal tumors. Of concern is that endocrine drugs used for chemoprevention in patients with germ-line mutant MutL, CHEK2, or ATM related breast cancer might be less
Research. . Transient transfection with siRNA against CHEK2 was conducted as previously (44) , and siRNA pools were purchased from Sigma Aldrich. Stable cell lines were established in the presence of specified antibiotics at recommended concentrations. Growth assays were conducted in triplicate and repeated independently as previously using Alamar blue to identify cell viability (44) . Growth assay results were plotted as fold change in growth from Day1 to Day7, and normalized to vehicle control where specified. 3D growth assays were conducted over 4-6 weeks with weekly drug treatments as previously (45) . Tumor growth assays in vivo were carried out as previously (46) by injecting 2-5x10 6 MCF7 cells into the L4 mammary fat pad/mouse. Mice for the MCF7 experiments were 4-6 week athymic nu/nu female mice (Envigo) and for the PDX experiments were 6-8 week female SCID/Bg mice, both from Charles River laboratory. Tumor volume was measured twice or thrice weekly using calipers to make
Research. Tumors were harvested at <2 cm diameter, and were embedded in paraffin blocks, OCT, and snap frozen as previously (47) . Mice that died within 3 weeks of tumor growth rate experiments were excluded from analysis. For all mouse experiments, investigator was blinded to groups and to outcomes. All mouse experiments were performed according to the IACUC rules and regulations (protocol#AN-6934).
Inhibitors and agonists
All drugs were maintained as stock solutions in DMSO, and stock solutions were stored at -80, and working stocks at -20 unless otherwise mentioned. 4-OHT (cat#H7904) and fulvestrant (cat#I4409) were purchased from Sigma-Aldrich and stocks were diluted to 10mM working stocks for all experiments other than dose curves, where specified concentrations were used.
For all experiments, cells were treated 24 hours after plating, and thereafter every 48 hours until completion of experiment. For mouse xenograft experiments, fulvestrant concentrations of 250mg/kg body weight were used. Beta-estradiol was purchased from Sigma-Aldrich (cat# E8875), maintained in sterile, nuclease free water, and diluted to obtain 10mM stocks for all experiments. For mouse xenograft experiments, 17 β-estradiol was added to the drinking water twice a week at a final concentration of 8μg/ml (cat#E2758, Sigma). Chk2 Inhibitor II hydrate (cat#C3742, Sigma-Aldrich), Chk1 inhibitor (PF-477736, cat#S2904, SelleckChem) and Chk2 activator (3, 3;-diindolyl methane, cat#sc-204624, Santa Cruz Biotechnology) were used at 10 and 100 nM, and 10 and 100 micromolar concentrations, respectively. Abemaciclib (LY2835219, cat#S7158, SelleckChem) and Palbociclib (PD-0332991, cat#S1116, SelleckChem) were used at 100 nM final concentrations for cell line assays and at 70 mg/kg/day in chow for tumor growth assays as previously (46) .
Immunostaining, Comet assay and Microscopy
Research. 
Western blotting, gene expression array, RPPA and phospho-proteomics
Western blotting was conducted as previously described Cyclophilin-A (cat#2175, 1:5000). The gene expression array (Qiagen) was used according to manufacturer's instructions. Reverse phase protein array (RPPA) assays were carried out as described previously with minor modifications (48) . Phospho-proteomics data and methodologies for analysis were performed also as described previously (22).
Statistical Analysis
ANOVA or Student's T-test was used for independent samples with normal distribution. Where distribution was not normal (assessed using Q-Q plots with the Wilk-Shapiro test of normality), either the Kruskal-Wallis or Wilcoxon Rank Sum test was used. All experiments were conducted in triplicate and each experiment was duplicated independently >2 times. These criteria were formulated to ensure that results from each dataset were calculable within the range of sensitivity of the statistical test used. Databases used for human data mining are from publically available resources: Oncomine, cBio (49) and COSMIC (50) . Z1031/POL dataset was used with permission from the Alliance consortium. All patients provided informed consent, studies were conducted according to ethical guidelines and with IRB approval. Lists of DDR genes for initial analyses were obtained from the KEGG database, and list of MMR genes was restricted to 
MLH1, PMS1, PMS2, MLH3, MSH2, MSH3, MSH4, MSH5, MSH6, PMS2L3, and EXO1. MutL
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